According to filings with the U.S. Securities and Exchange Commission, Novasenta is raising up to $30,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Mani Mohindru played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Novasenta
Novasenta discovers novel therapeutic targets to develop innovative and effective treatments with the goal of transforming the lives of patients with cancer. We use systematic, rigorous, and unbiased human tumor microenvironment analysis to uncover new druggable targets, exploiting the critical interplay of disease, immune response, and metabolism. Single-cell level analysis of high-quality, human tumor samples combined with the advanced data mining abilities of our research and computational biology teams accelerate the path from discovery to patient. Our goal is to identify novel targets to generate effective therapies for a range of cancers.

To learn more about Novasenta, visit http://novasenta.com/

Contact:
Mani Mohindru, Chief Executive Officer
412-621-6200
https://www.linkedin.com/in/mani-mohindru-phd-2909a55/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.